Janssen announces phase 1 results for amivantamab in advanced NSCLC harbouring Exon 20 insertion mutations

This article was originally published here

Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation. Investigators assessed efficacy using overall response rate (ORR) per

The post Janssen announces phase 1 results for amivantamab in advanced NSCLC harbouring Exon 20 insertion mutations appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply